Intelligence · Clinical Development
Pipeline search results
Programs matching “pembrolizumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 75 pipeline programs matching "pembrolizumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Combination Treatment of PDS0101 and Pembrolizumab
PDS Biotechnology Corp
Recurrent Head and Neck Cancer
1 trial -
Lifileucel plus Pembrolizumab
Iovance Biotherapeutics B.V.
Metastatic Melanoma
1 trial -
PEMBROLIZUMAB
Ningbo Cancer Hospital
Squamous cell carcinoma of head and neck
1 trial -
PEMBROLIZUMAB
Ningbo Cancer Hospital
Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.
1 trial -
PEMBROLIZUMAB , BNT113
BioNTech SE
Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer
1 trial -
Pembrolizumab
Eisai Co.,
Endometrial Neoplasms
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Renal Cell Carcinoma
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Urinary Bladder Neoplasms
1 trial -
Pembrolizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Ovarian Cancer
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Metastatic Esophageal Squamous Cell Carcinoma
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Triple Negative Breast Neoplasms
1 trial -
Pembrolizumab
Incyte
Renal Cell Carcinoma (RCC)
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Solid Tumors
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Cervical Cancer
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Carcinoma, Renal Cell
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Endometrial Neoplasms
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Gastric Neoplasms
1 trial -
Pembrolizumab (K)
Merck KGaA, Darmstadt, Germany
Breast Cancer
1 trial -
Pembrolizumab 25 MG/ML [Keytruda]
United Therapeutics Europe Ltd
Lung Cancer, Nonsmall Cell
1 trial -
Pembrolizumab/Vibostolimab
Merck KGaA, Darmstadt, Germany
Lung Neoplasms
1 trial -
QL2107, PEMBROLIZUMAB
Lacuna Pharma Pty Ltd
Non-small cell lung cancer
1 trial -
UC-0107/1718
Ningbo Cancer Hospital
Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line
1 trial -
favezelimab/pembrolizumab
Merck KGaA, Darmstadt, Germany
Colorectal Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.